News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
697,003 Results
Type
Article (42478)
Company Profile (279)
Press Release (654246)
Section
Business (205275)
Career Advice (2063)
Deals (35546)
Drug Delivery (93)
Drug Development (82179)
Employer Resources (170)
FDA (16237)
Job Trends (14991)
News (347913)
Policy (32955)
Tag
Academia (2618)
Alliances (49425)
Alzheimer's disease (1236)
Approvals (16167)
Artificial intelligence (130)
Bankruptcy (354)
Best Places to Work (11674)
Biotechnology (200)
Breast cancer (120)
Cancer (1093)
Cardiovascular disease (99)
Career advice (1725)
Cell therapy (241)
Clinical research (65252)
Collaboration (388)
Compensation (200)
COVID-19 (2579)
C-suite (95)
Data (1132)
Diabetes (154)
Diagnostics (6204)
Earnings (84997)
Employer resources (148)
Events (111421)
Executive appointments (312)
FDA (16778)
Funding (356)
Gene therapy (184)
GLP-1 (599)
Government (4424)
Healthcare (19049)
Infectious disease (2664)
Inflammatory bowel disease (109)
Interviews (317)
IPO (16380)
Job creations (3675)
Job search strategy (1476)
Layoffs (417)
Legal (7976)
Lung cancer (170)
Manufacturing (176)
Medical device (13266)
Medtech (13271)
Mergers & acquisitions (19248)
Metabolic disorders (414)
Neuroscience (1516)
NextGen Class of 2024 (6640)
Non-profit (4640)
Northern California (1485)
Obesity (241)
Opinion (188)
Patents (102)
People (56940)
Phase I (20234)
Phase II (28701)
Phase III (21425)
Pipeline (459)
Postmarket research (2687)
Preclinical (8688)
Radiopharmaceuticals (241)
Rare diseases (223)
Real estate (5959)
Regulatory (21830)
Research institute (2360)
Resumes & cover letters (353)
Southern California (1305)
Startups (3588)
United States (13565)
Vaccines (556)
Weight loss (176)
Date
Today (77)
Last 7 days (674)
Last 30 days (3731)
Last 365 days (35950)
2024 (32999)
2023 (40362)
2022 (51490)
2021 (56028)
2020 (54588)
2019 (47263)
2018 (35571)
2017 (32482)
2016 (32010)
2015 (38089)
2014 (31883)
2013 (27007)
2012 (29252)
2011 (29918)
2010 (28248)
Location
Africa (739)
Arizona (193)
Asia (37689)
Australia (6216)
California (3338)
Canada (1296)
China (256)
Colorado (148)
Connecticut (153)
Europe (81148)
Florida (461)
Georgia (118)
Illinois (347)
Indiana (197)
Kansas (97)
Maryland (579)
Massachusetts (2631)
Michigan (160)
Minnesota (274)
New Jersey (962)
New York (965)
North Carolina (708)
Northern California (1485)
Ohio (139)
Pennsylvania (847)
South America (1138)
Southern California (1305)
Texas (466)
Utah (90)
Washington State (363)
697,003 Results for "american regent inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
American Regent introduces FDA-approved Epinephrine Injection, USP in 30 mL
October 29, 2024
·
8 min read
Policy
American Regent Introduces Potassium Phosphates, USP; FDA-Approved and “AP” Rated¹
American Regent announces the launch and availability of Potassium Phosphates Injection, USP, which is FDA-approved and therapeutically equivalent to Potassium Phosphates.1 Potassium Phosphates Injection, USP is indicated as a source of phosphorus:
October 19, 2023
·
9 min read
Pharm Country
American Regent Introduces Levocarnitine Injection, USP; FDA-Approved, AP Rated, and Therapeutically Equivalent to Carnitor®¹
American Regent announces the release and availability of Levocarnitine Injection, USP, FDA-approved, “AP” rated, and therapeutically equivalent to Carnitor®.
October 10, 2023
·
6 min read
Drug Development
American Regent Announces Results From Phase 3 HEART-FID Trial with INJECTAFER®
American Regent, Inc., a Daiichi Sankyo Group company, announced results from the phase 3 HEART-FID trial of INJECTAFER® for the treatment of iron deficiency in adult heart failure patients with reduced ejection fraction.
August 26, 2023
·
12 min read
Deals
Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance
Oragenics, Inc. today announced that it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) dated June 18, 2024, notifying the Company that it has accepted the Company’s plan to regain compliance with NYSE American’s continued listing standards.
June 20, 2024
·
2 min read
Pharm Country
American Regent introduces FDA-approved Epinephrine Injection, USP
American Regent announces the launch of sulfite-free Epinephrine Injection, USP.
March 30, 2023
·
7 min read
BioCapital
Senseonics Holdings, Inc. to Host Business Update and Analyst Event During the American Diabetes Association’s 84th Scientific Sessions
Senseonics Holdings, Inc. announced plans to host a business update and analyst event during the American Diabetes Association’s 84th Scientific Sessions in Orlando, FL.
June 13, 2024
·
1 min read
Press Releases
NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)
October 21, 2024
·
3 min read
Policy
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
Oragenics, Inc., a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, announced that it received a notice from the NYSE American LLC dated April 18, 2024, notifying the Company that it is no longer in compliance with NYSE American continued listing standards.
April 19, 2024
·
4 min read
Pharm Country
American Regent Launches a New Vial Presentation
American Regent, Inc. and Provepharm Life Solutions are pleased to announce the availability of ProvayBlue® Injection, USP in a 10 mL single-dose vial.
June 30, 2022
·
11 min read
1 of 69,701
Next
